Apolipoprotein e regulation of myeloid cell plasticity in atherosclerosis

Current Opinion in Lipidology

Volumn 23, Issue 5, 2012, Pages 471-478

  Raffai, Robert L ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

apolipoprotein E; atherosclerosis; macrophage; monocyte

Indexed keywords

ABC TRANSPORTER A1; ABC TRANSPORTER G1; APOLIPOPROTEIN A1; APOLIPOPROTEIN E; APOLIPOPROTEIN E4; CHOLESTEROL; HIGH DENSITY LIPOPROTEIN; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; MITOGEN ACTIVATED PROTEIN KINASE P38; STAT5 PROTEIN;

ATHEROSCLEROSIS; BLOOD VESSEL WALL; BONE MARROW CELL; CELL ACTIVATION; CELL POLARITY; CELL PROLIFERATION; HEMATOPOIETIC STEM CELL; HUMAN; HYPERLIPIDEMIA; IMMUNOCOMPETENT CELL; INFLAMMATION; LIPID DIET; MACROPHAGE; MOLECULAR INTERACTION; MOLECULAR MECHANICS; MONOCYTE; MONOCYTOSIS; NONHUMAN; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN FUNCTION; REVIEW;

ANIMALS; APOLIPOPROTEINS E; ATHEROSCLEROSIS; CELL POLARITY; CELL PROLIFERATION; CHOLESTEROL; HEMATOPOIETIC STEM CELLS; HUMANS; HYPERLIPIDEMIAS; INFLAMMATION MEDIATORS; MACROPHAGES; MEMBRANE MICRODOMAINS; MICE; MONOCYTES; MYELOID CELLS; PROTEIN INTERACTION DOMAINS AND MOTIFS; RECEPTORS, LDL;

EID: 84866319499     PISSN: 09579672     EISSN: 14736535     Source Type: Journal    
DOI: 10.1097/MOL.0b013e328356f967     Document Type: Review

References (74)

1. Libby P, Ridker PM, Hansson GK. Progress and challenges in translating the biology of atherosclerosis. Nature 2011; 473:317-325.
2. Drechsler M, Megens RT, van Zandvoort M, et al. Hyperlipidemia-triggered neutrophilia promotes early atherosclerosis. Circulation 2010; 122:1837-1845.
3. Swirski FK, Pittet MJ, Kircher MF, et al. Monocyte accumulation in mouse atherogenesis is progressive and proportional to extent of disease. Proc Natl Acad Sci USA 2006; 103:10340-10345. (Pubitemid 44051168)
4. Swirski FK, Libby P, Aikawa E, et al. Ly-6Chi monocytes dominate hyperch-olesterolemia-associated monocytosis and give rise to macrophages in atheromata. J Clin Invest 2007; 117:195-205. (Pubitemid 46048466)
5. Tacke F, Alvarez D, Kaplan TJ, et al. Monocyte subsets differentially employ CCR2, CCR5, and CX3CR1 to accumulate within atherosclerotic plaques. J Clin Invest 2007; 117:185-194. (Pubitemid 46048465)
6. Libby P, Nahrendorf M, Pittet MJ, Swirski FK. Diversity of denizens of the atherosclerotic plaque: not all monocytes are created equal. Circulation 2008; 117:3168-3170.
7. Robbins CS, Swirski FK. The multiple roles of monocyte subsets in steady state and inflammation. Cell Mol Life Sci 2010; 67:2685-2693.
8. Mantovani A, Garlanda C, Locati M. Macrophage diversity and polarization in atherosclerosis: a question of balance. Arterioscler Thromb Vasc Biol 2009; 29:1419-1423.
9. Adamson S, Leitinger N. Phenotypic modulation of macrophages in response to plaque lipids. Curr Opin Lipidol 2011; 22:335-342.
10. Getz GS, Reardon CA. Apoprotein E as a lipid transport and signaling protein in the blood, liver, and artery wall. J Lipid Res 2009; 50 (Suppl):S156-S161.
11. Mahley RW, Weisgraber KH, Huang Y. Apolipoprotein E: structure determines function,;1; from atherosclerosis to Alzheimer's disease to AIDS. J Lipid Res 2009; 50 (Suppl):S183-S188.
12. Davignon J. Apolipoprotein E and atherosclerosis: beyond lipid effect. Arter-ioscler Thromb Vasc Biol 2005; 25:267-269. (Pubitemid 40189142)
13. Curtiss LK, Boisvert WA. Apolipoprotein E and atherosclerosis. Curr Opin Lipidol 2000; 11:243-251. (Pubitemid 30336021)
14. Zhang SH, Reddick RL, Piedrahita JA, Maeda N. Spontaneous hypercholes-terolemia and arterial lesions in mice lacking apolipoprotein E. Science 1992; 258:468-471.
15. Plump AS, Smith JD, Hayek T, et al. Severe hypercholesterolemia and atherosclerosis in apolipoprotein E-deficient mice created by homologous recombination in ES cells. Cell 1992; 71:343-353.
16. Maeda N. Development of apolipoprotein E-deficient mice. Arterioscler Thromb Vasc Biol 2011; 31:1957-1962.
17. Linton MF, Hasty AH, Babaev VR, Fazio S. Hepatic apo E expression is required for remnant lipoprotein clearance in the absence of the low density lipoprotein receptor. J Clin Invest 1998; 101:1726-1736. (Pubitemid 28198503)
18. Mahley RW, Ji ZS. Remnant lipoprotein metabolism: key pathways involving cell-surface heparan sulfate proteoglycans and apolipoprotein E. J Lipid Res 1999; 40:1-16. (Pubitemid 29022581)
19. Raffäi RL, Hasty AH, Wang Y, et al. Hepatocyte-derived apoE is more effective than nonhepatocyte-derived apoE in remnant lipoprotein clearance. J Biol Chem 2003; 278:11670-11675. (Pubitemid 36792730)
20. Arai T, Rinninger F, Varban L, et al. Decreased selective uptake of high density lipoprotein cholesteryl esters in apolipoprotein E knock-out mice. Proc Natl Acad Sci USA 1999; 96:12050-12055. (Pubitemid 29502856)
21. Zhu Y, Bellosta S, Langer C, et al. Low-dose expression of a human apolipoprotein E transgene in macrophages restores cholesterol efflux capacity of apolipoprotein E-deficient mouse plasma. Proc Natl Acad Sci USA 1998; 95:7585-7590. (Pubitemid 28293296)
22. Bodzioch M, Orsó E, Klucken J, et al. The gene encoding ATP-binding cassette transporter 1 is mutated in Tangier disease. Nat Genet 1999; 22:347-351. (Pubitemid 29369524)
23. Marcil M, Brooks-Wilson A, Clee SM, et al. Mutations in the ABC1 gene in familial HDL deficiency with defective cholesterol efflux. Lancet 1999; 354:1341-1346. (Pubitemid 29481630)
24. Lawn RM, Wade DP, Garvin MR, et al. The Tangier disease gene product ABC1 controls the cellular apolipoprotein-mediated lipid removal pathway. J Clin Invest 1999; 104:R25-R31. (Pubitemid 29536327)
25. Matsuura F, Wang N, Chen W, et al. HDL from CETP-deficient subjects shows enhanced ability to promote cholesterol efflux from macrophages in an apoE-and ABCG1-dependent pathway. J Clin Invest 2006; 116:1435-1442.
26. Mahley RW, Huang Y, Weisgraber KH. Putting cholesterol in its place: apoE and reverse cholesterol transport. J Clin Invest 2006; 116:1226-1229.
27. Fazio S, Babaev VR, Murray AB, et al. Increased atherosclerosis in mice reconstituted with apolipoprotein E null macrophages. Proc Natl Acad Sci USA 1997; 94:4647-4652. (Pubitemid 27194297)
28. Hasty AH, Linton MF, Brandt SJ, et al. Retroviral gene therapy in apoE-deficient mice. ApoE expression in the artery wall reduces early foam cell lesion formation. Circulation 1999; 99:2571-2576. (Pubitemid 29228289)
29. Fazio S, Babaev VR, Burleigh ME, et al. Physiological expression of macro-phage apoE in the artery wall reduces atherosclerosis in severely hyperlipi-demic mice. J Lipid Res 2002; 43:1602-1609. (Pubitemid 35168274)
30. Venkateswaran A, Laffitte BA, Joseph SB, et al. Control of cellular cholesterol efflux by the nuclear oxysterol receptor LXR alpha. Proc Natl Acad Sci USA 2000; 97:12097-12102.
31. Chawla A, Boisvert WA, Lee CH, et al. APPAR gamma-LXR-ABCA1 pathway in macrophages is involved in cholesterol efflux and atherogenesis. Mol Cell 2001; 7:161-171. (Pubitemid 32162909)
32. Yvan-Charvet L, Wang N, Tall AR. Role of HDL, ABCA1, and ABCG1 Transporters in Cholesterol Efflux and Immune Responses. Arterioscler Thromb Vasc Biol 2010; 30:139-143.
33. Miyata M, Smith JD. Apolipoprotein E allele-specific antioxidant activity and effects on cytotoxicity by oxidative insults and b-amyloid peptides. Nat Genet 1996; 14:55-61. (Pubitemid 26301547)
34. Stannard AK, Riddell DR, Sacre SM, et al. Cell-derived apolipoprotein E (apoE) particles inhibit vascular cell adhesion molecule-1 (VCAM-1) expression in human endothelial cells. J Biol Chem 2001; 276:46011-46016.
35. Riddell DR, Graham A, Owen JS. Apolipoprotein E inhibits platelet aggregation through the L-arginine:nitric oxide pathway. Implications for vascular disease. J Biol Chem 1997; 272:89-95. (Pubitemid 27021129)
36. Grainger DJ, Reckless J, McKilligin E. Apolipoprotein E modulates clearance of apoptotic bodies in vitro and in vivo, resulting in a systemic proinflammatory state in apolipoprotein E-deficient mice. J Immunol 2004; 173:6366-6375. (Pubitemid 39487796)
37. Swertfeger DK, Hui DY. Apolipoprotein E receptor binding versus heparan sulfate proteoglycan binding in its regulation of smooth muscle cell migration and proliferation. J Biol Chem 2001; 276:25043-25048.
38. Swertfeger DK, Bu G, Hui DY. Low density lipoprotein receptor-related protein mediates apolipoprotein E inhibition of smooth muscle cell migration. J Biol Chem 2002; 277:4141-4146. (Pubitemid 34968674)
39. Bellosta S, Mahley RW, Sanan DA, et al. Macrophage-specific expression of human apolipoprotein E reduces atherosclerosis in hypercholesterolemic apolipoprotein E-null mice. J Clin Invest 1995; 96:2170-2179.
40. Thorngate FE, Rudel LL, Walzem RL, Williams DL. Low levels of extrahepatic nonmacrophage apoE inhibit atherosclerosis without correcting hypercho-lesterolemia in apoE-deficient mice. Arterioscler Thromb Vasc Biol 2000; 20:1939-1945. (Pubitemid 30644644)
41. Wientgen H, Thorngate FE, Omerhodzic S, et al. Subphysiologicapolipoprotein E (ApoE) plasma levels inhibit neointimal formation after arterial injury in ApoE-deficient mice. Arterioscler Thromb Vasc Biol 2004; 24:1460-1465. (Pubitemid 39050441)
42. Hui DY, Harmony JAK, Innerarity TL, Mahley RW. Immunoregulatory plasma lipoproteins. Role of apoprotein E and apoprotein B. J Biol Chem 1980; 255:11775-11781. (Pubitemid 11132191)
43. Pepe MG, Curtiss LK. Apolipoprotein E is a biologically active constituent of the normal immunoregulatory lipoprotein, LDL-In. J Immunol 1986; 136:3716-3723. (Pubitemid 16122069)
44. Kelly ME, Clay MA, Mistry MJ, et al. Apolipoprotein E inhibition of proliferation of mitogen-activated T lymphocytes: production of interleukin 2 with reduced biological activity. Cell Immunol 1994; 159:124-139. (Pubitemid 24381044)
45. Tenger C, Zhou X. Apolipoprotein E modulates immune activation by acting on the antigen-presenting cell. Immunology 2003; 109:392-397. (Pubitemid 36783265)
46. Ali K, Middleton M, Pure E, Rader DJ. Apolipoprotein E suppresses the type I inflammatory response in vivo. Circ Res 2005; 97:922-927. (Pubitemid 41552678)
47. Roselaar SE, Daugherty A. Apolipoprotein E-deficient mice have impaired innate immune responses to Listeria monocytogenes in vivo. J Lipid Res 1998; 39:1740-1743. (Pubitemid 28411160)
48. de Bont N, Netea MG, Demacker PNM, et al. Apolipoprotein E-deficient mice have an impaired immune response to Klebsiella pneumoniae. Eur J Clin Invest 2000; 30:818-822.
49. Van Oosten M, Rensen PC, Van Amersfoort ES, et al. Apolipoprotein Eprotects against bacterial lipopolysaccharide-induced lethality. A new therapeutic approach to treat gram-negative sepsis. J Biol Chem 2001; 276:8820-8824.
50. Kattan OM, Kasravi FB, Elford EL, et al. Apolipoprotein E-mediated immune regulation in sepsis. J Immunol 2008; 181:1399-1408.
51. Duan H, Li Z, Mazzone T. Tumor necrosis factor-a modulates monocyte/macrophage apoprotein Egene expression. J Clin Invest 1995; 96:915-922.
52. Brand K, Mackman N, Curtiss LK. Interferon-a inhibits macrophage apolipo-protein E production by posttranslational mechanisms. J Clin Invest 1993; 91:2031-2039. (Pubitemid 23141475)
53. Martinez FO, Sica A, Mantovani A, Locati M. Macrophage activation and polarization. Front Biosci 2008; 13:453-461. (Pubitemid 351599757)
54. Kadl A, Meher AK, Sharma PR, et al. Identification of a novel macrophage phenotype that develops in response to atherogenic phospholipids via Nrf2. Circ Res 2010; 107:737-746.
55. Khallou-Laschet J, Varthaman A, Fornasa G, et al. Macrophage plasticity in experimental atherosclerosis. PLoS One 2010; 5:e8852.
56. Feig JE, Parathath S, Rong JX, et al. Reversal of hyperlipidemia with a genetic switch favorably affects the content and inflammatory state of macrophages in atherosclerotic plaques. Circulation 2011; 123:989-998.
57. Feig JE, Rong JX, Shamir R, et al. HDL promotes rapid atherosclerosis regression in mice and alters inflammatory properties of plaque monocyte-derived cells. Proc Natl Acad Sci USA 2011; 108:7166-7171.
58. Serhan CN, Yang R, Martinod K, et al. Maresins: novel macrophage mediators with potent antiinflammatory and proresolving actions. J Exp Med 2009; 206:15-23.
59. Baitsch D, Bock HH, Engel T, et al. Apolipoprotein E induces antiinflammatory phenotype in macrophages. Arterioscler Thromb Vasc Biol 2011; 31:1160-1168.
60. Schneider WJ, Nimpf J. LDL receptor relatives at the crossroad of endocytosis and signaling. Cell Mol Life Sci 2003; 60:892-903. (Pubitemid 36735120)
61. Hiltunen TP, Luoma JS, Nikkari T, Yla-Herttuala S. Expression of LDL receptor, VLDL receptor, LDL receptor-related protein, and scavenger receptor in rabbit atherosclerotic lesions: marked induction of scavenger receptor and VLDL receptor expression during lesion development. Circulation 1998; 97:1079-1086.
62. Eck MV, Oost J, Goudriaan JR, et al. Role of the macrophage very-low-density lipoprotein receptor in atherosclerotic lesion development. Atherosclerosis 2005; 183:230-237. (Pubitemid 41579272)
63. Murphy AJ, Akhtari M, Tolani S, et al. ApoE regulates hematopoietic stem cell proliferation, monocytosis, and monocyte accumulation in atherosclerotic lesions in mice. J Clin Invest 2011; 121:4138-4149.
64. Yvan-Charvet L, Pagler T, Gautier EL, et al. ATP-binding cassette transporters and HDL suppress hematopoietic stem cell proliferation. Science 2010; 328:1689-1693.
65. Lin C-Y, Huang ZH, Mazzone T. Interaction with proteoglycans enhances the sterol efflux produced by endogenous expression of macrophage apoE. J Lipid Res 2001; 42:1125-1133. (Pubitemid 32645795)
66. Mahley RW. Apolipoprotein E: cholesterol transport protein with expanding role in cell biology. Science 1988; 240:622-630.
67. Rosenfeld ME, Butler S, Ord VA, et al. Abundant expression of apoprotein E by macrophages in human and rabbit atherosclerotic lesions. Arterioscler. Thromb 1993; 13:1382-1389. (Pubitemid 23271141)
68. Gaudreault N, Kumar N, Posada JM, et al. ApoE suppresses atherosclerosis by reducing lipid accumulation in circulating monocytes and the expression of inflammatory molecules on monocytes and vascular endothelium. Arterioscler Thromb Vasc Biol 2012; 32:264-272.
69. Raffäi RL, Weisgraber KH. Hypomorphic apolipoprotein E mice. A new model of conditional gene repair to examine apolipoprotein E-mediated metabolism. J Biol Chem 2002; 277:11064-11068. (Pubitemid 34952865)
70. Getz GS, Reardon CA. Diet and murine atherosclerosis. Arterioscler Thromb Vasc Biol 2006; 26:242-249. (Pubitemid 43732181)
71. Raffäi RL, Dong L-M, Farese RV Jr, Weisgraber KH. Introduction of human apolipoprotein E4 'domain interaction' into mouse apolipoprotein E. Proc Natl Acad Sci USA 2001; 98:11587-11591. (Pubitemid 32928772)
72. Eberlé D, Kim RY, Luk FS, et al. Apolipoprotein E4 domain interaction accelerates diet-induced atherosclerosis in hypomorphic Arg-61 Apoe mice. Arterioscler Thromb Vasc Biol 2012; 32:1116-1123.
73. Murphy AJ, Westerterp M, Yvan-Charvet L, Tall AR. Antiatherogenic mechanisms of high density lipoprotein: Effects on myeloid cells. Biochim Biophys Acta 2012; 1821:513-521.
74. Norata GD, Pirillo A, Catapano AL. HDLs, immunity, and atherosclerosis. Curr Opin Lipidol 2011; 22:410-416.